Tag Archives: NASDAQ:SLS

Oppenheimer Thinks SELLAS Life Sciences Group Inc’s Stock is Going to Recover

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on SELLAS Life Sciences Group Inc (SLS – Research Report), with a price target of $13. The company’s shares opened today at $1.02, close to its 52-week

Analyst Explains Why They Downgraded Their Rating on SELLAS Life Sciences Group Inc (SLS)

SELLAS Life Sciences Group Inc (SLS – Research Report) received a Hold rating from Maxim Group analyst Jason McCarthy today. The company’s shares opened today at $1.26, close to its 52-week low of $0.80. McCarthy observed: “Sellas reported FYE18 with

Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group Inc (NASDAQ: SLS) and Arena Pharma (NASDAQ: ARNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SELLAS Life Sciences Group Inc (SLS – Research Report) and Arena Pharma (ARNA – Research Report) with bullish sentiments. SELLAS Life Sciences

SELLAS Life Sciences Group Inc (SLS) Receives a Buy from Oppenheimer

Oppenheimer analyst Hartaj Singh maintained a Buy rating on SELLAS Life Sciences Group Inc (SLS – Research Report) today and set a price target of $13. The company’s shares opened today at $1.82, close to its 52-week low of $0.80.

Maxim Group Keeps a Buy Rating on SELLAS Life Sciences Group Inc (SLS)

Maxim Group analyst Jason McCarthy maintained a Buy rating on SELLAS Life Sciences Group Inc (NASDAQ: SLS) today and set a price target of $5. The company’s shares opened today at $1.99, close to its 52-week low of $0.80. McCarthy

SELLAS Life Sciences Group Inc Gets a Buy Rating from Maxim Group

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to SELLAS Life Sciences Group Inc (NASDAQ: SLS), with a price target of $13. The company’s shares opened today at $6.60. McCarthy said: “The prior interim